Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Glutamate-Sensitive Contrast: Marker for Disability
Mult Scler; ePub 2018 Sep 19; O’Grady, et al
Glutamate-sensitive contrast was significantly increased in the prefrontal cortex of patients with multiple sclerosis (MS) with accumulated disability, according to a recent study. In addition, glutamate-sensitive contrast in the prefrontal cortex was significantly correlated with symbol digit modality test (rs = −0.814) and choice reaction time (rs = 0.772) scores in patients, suggesting that glutamate-sensitive chemical exchange saturation transfer (GluCEST) MRI may have utility as a marker for gray matter (GM) pathology and cognitive impairment (CI). A total of 20 patients with relapsing-remitting MS and 20 healthy controls underwent cognitive testing, anatomical imaging, and GluCEST imaging. Glutamate-sensitive image contrast was quantified for cortical GM, compared between cohorts, and correlated with clinical measures of CI. Researchers also found that glutamate-sensitive contrast in the prefrontal cortex was significantly correlated with symbol digit modality test (rs = −0.814) and choice reaction time (rs = 0.772) scores in patients, suggesting that GluCEST MRI may have utility as a marker for GM pathology and CI.
O’Grady KP, Dula AN, Lyttle DD, et al. Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis. [Published online ahead of print September 19, 2018]. Mult Scler. doi:10.1177/1352458518799583.